Co-expression of tetanus toxin fragment C in Escherichia coli with thioredoxin and its evaluation as an effective subunit vaccine candidate

Vaccine

Volumn 29, Issue 35, 2011, Pages 5978-5985

  Yu, Yun Zhou ^a   Gong, Zheng Wei ^a   Ma, Yao ^a   Zhang, Shu Ming ^b   Zhu, Heng Qi ^a   Wang, Wen Bing ^a   Du, Yun ^a   Wang, Shuang ^a   Yu, Wei Yuan ^a   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

Clostridium tetani; Fragment C; Ganglioside; Tetanus toxin; Vaccine

Indexed keywords

TETANUS TOXIN; TETANUS TOXOID; THIOREDOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG SCREENING; ESCHERICHIA COLI; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TETANUS; TETANUS PROPHYLAXIS; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ESCHERICHIA COLI; FEMALE; GANGLIOSIDES; HUMANS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; SURVIVAL ANALYSIS; TETANUS; TETANUS TOXIN; TETANUS TOXOID; THIOREDOXINS; VACCINATION; VACCINES, SUBUNIT;

EID: 79960731311     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.039     Document Type: Article

References (45)

1. Montecucco C., Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 1995, 8(4):423-472.
2. Lalli G., Herreros J., Osborne S.L., Montecucco C., Rossetto O., Schiavo G. Functional characterisation of tetanus and botulinum neurotoxins binding domains. J Cell Sci 1999, 112:2715-2724.
3. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000, 80:717-766.
4. Turton K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002, 27:552-558.
5. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82:955-966.
6. Middlebrook J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv Drug Deliv Rev 2005, 57:1415-1423.
7. Behrensdorf-Nicol H.A., Kegel B., Bonifas U., Silberbach K., Klimek J., Weiber K., et al. Residual enzymatic activity of the tetanus toxin light chain present in tetanus toxoid batches used for vaccine production. Vaccine 2008, 26(31):3835-3841.
8. Fairweather N.F., Lyness V.A., Maskell D.J. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun 1987, 55(11):2541-2545.
9. Makoff A.J., Ballantine S.P., Smallwood A.E., Fairweather N.F. Expression of tetanus toxin fragment C in E. coli: its purification and potential use as a vaccine. Nat Biotechnol 1989, 7:1043-1046.
10. Makoff A.J., Oxer M.D., Romanos M.A., Fairweather N.F., Ballantinel S. Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons. Nucleic Acids Res 1989, 17:10191-10202.
11. Halpern J.L., Habig W.H., Neale E.A., Stibitz S. Cloning and expression of functional fragment C of tetanus toxin. Infect Immun 1990, 58(4):1004-1009.
12. Romanos M.A., Makoff A.J., Fairweather N.F., Beesley K.M., Slater D.E., Rayment F.B., et al. Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA. Nucleic Acids Res 1991, 19:1461-1467.
13. Ribas A.V., Ho P.L., Tanizaki M.M., Raw I., Nascimento A.L. High-level expression of tetanus toxin fragment C-thioredoxin fusion protein in Escherichia coli. Biotechnol Appl Biochem 2000, 31(Pt 2):91-94.
14. Varfolomeeva N.A., Makhotina O.A., Sergeeva T.I., Belyǐ Iu.F. Production of recombinant fragments of the Clostridium tetani neurotoxin for the development of new immune-prophylaxis preparations against tetanus. Mol Gen Mikrobiol Virusol 2003, 3:29-33.
15. Qazi O., Sesardic D., Tierney R., Soderback Z., Crane D., Bolgiano B., et al. Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines. Infect Immun 2006, 74(8):4884-4891.
16. Yu R., Hou L., Yu C., Liu S., Ren J., Fang T., et al. Enhanced expression of soluble recombinant tetanus neurotoxin Hc in Escherichia coli as a tetanus vaccine candidate. Immunobiology 2011, 216(4):485-490.
17. Halpern J.L., Loftus A. Characterization of the receptor binding domain of tetanus toxin. J Biol Chem 1993, 268:11188-11192.
18. Sinha K., Box M., Lalli G., Schiavo G., Schneider H., Groves M., et al. Analysis of mutants of tetanus toxin HC fragment: ganglioside binding, cell binding and retrograde axonal transport properties. Mol Microbiol 2000, 37:1041-1051.
19. Emsley P., Fotinou C., Black I., Fairweather N.F., Charles I.G., Watts C., et al. The structures of the H(C) fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding. J Biol Chem 2000, 275(12):8889-8894.
20. Rummel A., Bade S., Alves J., Bigalke H., Binz T. Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity. J Mol Biol 2003, 326(3):835-847.
21. Stratford R., Douce G., Zhang-Barber L., Fairweather N., Eskola J., Dougan G. Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine 2000, 19(7-8):810-815.
22. Stratford R., Douce G., Bowe F., Dougan G. A vaccination strategy incorporating DNA priming and mucosal boosting using tetanus toxin fragment C (TetC). Vaccine 2001, 20(3-4):516-525.
23. Stevenson A., Roberts M. Intranasal immunisation against tetanus with an attenuated Bordetella bronchiseptica vector expressing FrgC: improved immunogenicity using a Bvg-regulated promoter to express FrgC. Vaccine 2004, 22:4300-4305.
24. Lee S., Belitsky B.R., Brown D.W., Brinker J.P., Kerstein K.O., Herrmann J.E., et al. Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C. Vaccine 2010, 28(41):6658-6665.
25. Tregoning J.S., Nixon P., Kuroda H., Svab Z., Clare S., Bowe F., et al. Expression of tetanus toxin Fragment C in tobacco chloroplasts. Nucleic Acids Res 2003, 31(4):1174-1179.
26. Tregoning J., Maliga P., Dougan G., Nixon P.J. New advances in the production of edible plant vaccines: chloroplast expression of a tetanus vaccine antigen, TetC. Phytochemistry 2004, 65(8):989-994.
27. Chargelegue D., Drake P.M., Obregon P., Prada A., Fairweather N., Ma J.K. Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants. Infect Immun 2005, 73(9):5915-5922.
28. Padua R.A., Larghero J., Robin M., le Pogam C., Schlageter M.H., Muszlak S., et al. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 2003, 9(11):1413-1417.
29. Bongat A.F., Saksena R., Adamo R., Fujimoto Y., Shiokawa Z., Peterson D.C., et al. Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant. Glycoconj J 2010, 27(1):69-77.
30. Iurescia S., Fioretti D., Pierimarchi P., Signori E., Zonfrillo M., Tonon G., et al. Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma. J Biomed Biotechnol 2010, 31:60-69.
31. Patel K.G., Ng P.P., Levy S., Levy R., Swartz J.R. Escherichia coli-based production of a tumor idiotype antibody fragment-tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. Protein Expr Purif 2011, 75(1):15-20.
32. Roux S., Saint Cloment C., Curie T., Girard E., Brûlet P., Molgó J. C-terminal fragment of tetanus toxin: its use in neuronal network analysis and its potential as non-viral vector. J Soc Biol 2005, 199(1):35-44.
33. Andreu A., Fairweather N., Miller A.D. Clostridium neurotoxin fragments as potential targeting moieties for liposomal gene delivery to the CNS. Chembiochem 2008, 9(2):219-231.
34. Li J., Chian R.J., Ay I., Kashi B.B., Celia S.A., Tamrazian E., et al. Insect GDNF: TTC fusion protein improves delivery of GDNF to mouse CNS. Biochem Biophys Res Commun 2009, 390(3):947-951.
35. Oliveira H., Fernandez R., Pires L.R., Martins M.C., Simões S., Barbosa M.A., et al. Targeted gene delivery into peripheral sensorial neurons mediated by self-assembled vectors composed of poly(ethylene imine) and tetanus toxin fragment c. J Control Release 2010, 143(3):350-358.
36. Moreno-Igoa M., Calvo A.C., Penas C., Manzano R., Oliván S., Muñoz M.J., et al. Fragment C of tetanus toxin, more than a carrier. Novel perspectives in non-viral ALS gene therapy. J Mol Med 2010, 88(3):297-308.
37. Yu Y.Z., Sun Z.W., Li N., Wang S., Wang R.L., Yu W.Y. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol 2008, 15:1819-1823.
38. Yu Y.Z., Li N., Zhu H.Q., Wang R.L., Du Y., Wang S., et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009, 27:2816-2822.
39. Yu Y.Z., Sun Z.W., Li N., Wang S., Wang R.L., Yu W.Y. Protection with a recombinant Hc of Clostridium botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine. Immunopharmacol Immunotoxicol 2009, 31(2):261-266.
40. Yu Y.Z., Zhang S.M., Ma Y., Zhu H.Q., Wang W.B., Du Y., et al. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Clin Immunol 2010, 137(2):271-280.
41. 2 antitoxin against botulinum neurotoxin serotype A. Biochimie 2010, 92(10):1315-1320.
42. Chinese Pharmacopoeia Commission Pharmacopoeia of the People's Republic of China (Volume III), Appendix XI F: the potency assay of tetanus antitoxin 2005, People's Medical Publishing House, Beijing, Appendix p. 68.
43. Baldwin M.R., Tepp W.H., Przedpelski A., Pier C.L., Bradshaw M., Johnson E.A., et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008, 76:1314-1318.
44. Mansour A.A., Mousavi S.L., Rasooli I., Nazarian S., Amani J., Farhadi N. Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E. Biologicals 2010, 38(2):260-264.
45. Behrensdorf-Nicol H.A., Bonifas U., Kegel B., Silberbach K., Kramer B., Weisser K. In vitro determination of tetanus toxicity by an endopeptidase assay linked to a ganglioside-binding step. Toxicol In Vitro 2010, 24(3):988-994.